NCT03927105: A trial that was reported late by University of Michigan Rogel Cancer Center
This trial has reported, although it was 285 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03927105 |
|---|---|
| Title | Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 25, 2019 |
| Completion date | Nov. 1, 2019 |
| Required reporting date | Oct. 31, 2020, midnight |
| Actual reporting date | Aug. 13, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 285 |